A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 09 Mar 2018 New trial record